BELGRADE, MT , Nov. 12, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that it will release its financial results for the quarter and year to date ended September 30,

BELGRADE, MT , Oct. 15, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today the appointment of Michael Mainelli to serve as Interim Chief Executive

BELGRADE, MT , Sept. 17, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings , Inc. (NYSE American: XTNT), a leader in the development and commercialization of regenerative medicine products and medical devices, today announced it has executed amendments to its credit facility reducing interest

BELGRADE, MT , Aug. 20, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings , Inc. (NYSE American: XTNT), a leader in the development and commercialization of regenerative medicine products and medical devices, today announced the appointment of Kathie Lenzen as chief financial officer, effective

BELGRADE, MT , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings , Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today reported financial and operating results for the second quarter ended June 30, 2018 .

BELGRADE, MT , Aug. 06, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today announces that it will release its financial results for the quarter ended June 30, 2018 , after the close of

BELGRADE, MT , July 10, 2018 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced the appointment of Kevin Brandt to the new executive position of Chief Commercial Officer effective

BELGRADE, MT , June 19, 2018 (GLOBE NEWSWIRE) -- Xtant TM Medical Holdings, Inc. (NYSE American: XTNT) announces that the subscription period for its previously announced rights offering (the “Offering”) of shares of the Company’s common stock at a subscription price of $7.20 per share expired on

BELGRADE, MT / ACCESSWIRE / May 21, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, announces U.S. Food and Drug Administration (FDA) 510(k) clearance for InTice™-C Porous Titanium Cervical Interbody

BELGRADE, MT / ACCESSWIRE / May 8, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, today reported financial and operating results for the first quarter of 2018.